The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
RemeGen Co Forward PE Ratio Related Terms
RemeGen Co Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for RemeGen Co's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co Forward PE Ratio Chart
RemeGen Co Annual Data
Trend
Forward PE Ratio
RemeGen Co Quarterly Data
Forward PE Ratio
FRA:REG vs VRTX, REGN, ALNY: Forward PE Ratio Comparison
For the Biotechnology subindustry, RemeGen Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
RemeGen Co (FRA:REG) has a Forward PE Ratio of 13.45 as of Jul. 11, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #149 out of 354 companies in the Biotechnology industry, placing it in the top 42.1%.
Is RemeGen Co's Forward PE Ratio too high?
RemeGen Co's current Forward PE Ratio is 13.45. The Biotechnology industry median Forward PE Ratio is 21.90. RemeGen Co's value of 13.45 is 38.6% below this industry median. Based on the distribution chart, RemeGen Co ranks #149 out of 354 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RemeGen Co has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Forward PE Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #149 out of 354 companies for Forward PE Ratio. This puts RemeGen Co in the upper half of its industry. The industry median Forward PE Ratio is 21.90. RemeGen Co's value of 13.45 is 38.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.90, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RemeGen Co's current Forward PE Ratio of 13.45 is 38.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on RemeGen Co and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RemeGen Co's current Forward PE Ratio is 13.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €15.26, compared to a current price of €9.36 — trading 38.7% below its estimated fair value. The current Forward PE Ratio is 13.45 and 38.6% below the Biotechnology industry median of 21.90. RemeGen Co's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Forward PE Ratio is 13.45 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €9.36 is trading 38.7% below its estimated GF Value™ of €15.26.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
Forward PE Ratio: 13.45
GF Value™: €15.26 vs. price of €9.36 (38.7% below fair value)
Industry Position: 38.6% below the Biotechnology median (#149 of 354)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
39GF Score
Get the complete analysis for FRA:REG
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 